Medical management of hyperparathyroidism includes which of the following?
**Core Concept**
Hyperparathyroidism is a disorder of calcium and phosphate metabolism caused by an overproduction of parathyroid hormone (PTH) due to parathyroid gland abnormalities. The primary goal of medical management is to reduce PTH levels, alleviate symptoms, and prevent complications such as renal calculi and osteoporosis.
**Why the Correct Answer is Right**
The correct answer is **B. Bisphosphonates**. Bisphosphonates, such as alendronate or risedronate, act by inhibiting osteoclast-mediated bone resorption, thereby reducing the release of calcium from bone into the bloodstream. This helps to decrease PTH levels and alleviate symptoms associated with hyperparathyroidism. Additionally, bisphosphonates have been shown to improve bone density and reduce the risk of osteoporotic fractures.
**Why Each Wrong Option is Incorrect**
**Option A:** **Calcitonin** is a hormone that lowers blood calcium levels by inhibiting osteoclast activity and increasing renal calcium excretion. While calcitonin may be used in the management of hypercalcemia, it is not a first-line treatment for hyperparathyroidism.
**Option C:** **Vitamin D analogues** may actually worsen hyperparathyroidism by further increasing PTH levels and calcium absorption from the gut. These agents are typically reserved for patients with vitamin D deficiency or insufficiency.
**Clinical Pearl / High-Yield Fact**
In patients with asymptomatic primary hyperparathyroidism, medical management with bisphosphonates or vitamin D analogues may be considered in addition to surgery, especially in those with significant bone density loss or other risk factors for osteoporosis.
**Correct Answer: B. Bisphosphonates**